Evotec OAI Successfully Completes Assay Development Programme with ALTANA Pharma AG

05-Nov-2002

Evotec OAI, a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, announced today the successful completion of its assay development programme with ALTANA Pharma AG.

In close collaboration with scientists at ALTANA Pharma Evotec OAI has developed a new and complex assay programme using Evotec OAI's novel confocal imaging reader for fast high-content cell analysis ("Opera"). In March Evotec OAI passed the first milestone by successfully demonstrating a novel assay principle. Phase II, the assay optimisation, has now been completed which is proving Evotec OAI's expertise in miniaturised assay development and related technology developments. ALTANA Pharma will receive the cell analyzer "Opera" by the end of the year and will integrate it into their discovery unit. As a result of an excellent collaboration to date, ALTANA Pharma decided to commission Evotec OAI to add additional features to the device, further enhancing the capabilities of the instrument.

Joern Aldag, President and Chief Executive Officer of Evotec OAI, said: "We are pleased to have completed this challenging programme with excellent results and to have contributed innovative tools to our partner's drug discovery efforts. This collaboration validates our world class expertise in developing novel drug discovery solutions tailored to our customers' research needs."

Dr. U. Thibaut, ALTANA Pharma's Vice President of Discovery Research, said: "Our partnership with Evotec OAI is highly satisfactory. The communication in this important collaboration is open and the scientific standards of the project are very high. The assay development programme we started together with Evotec OAI was highly successful and will help us to further reduce assay development times significantly. In addition, the programme also demonstrated the excellent performance of the "Opera" reader, which will be integrated into one of our HTS systems."

https://www.chemeurope.com/en/news/15577/evotec-oai-successfully-completes-assay-development-programme-with-altana-pharma-ag.html